

Avilex Pharma ApS

Ole Maaløes Vej 3, 2200 København N

CVR no. 34 89 68 28

Annual report

for the year 1 January - 31 December 2022

Approved at the Company's annual general meeting on 3 July 2023

Chair of the meeting:

.....
Kristian Strømgaard

Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements 1 January - 31 December	7
Income statement	7
Balance sheet	8
Statement of changes in equity	9
Notes to the financial statements	10

Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Avilex Pharma ApS for the financial year 1 January - 31 December 2022.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December 2022.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 3 July 2023
Executive Board:

.....
Kristian Strømgaard

Board of Directors:

.....
Raymond George Hill
Chairman

.....
Kristian Strømgaard

.....
Morten Døssing

.....
Jonathan Mark Treherne

Independent auditor's report

To the shareholders of Avilex Pharma ApS

Opinion

We have audited the financial statements of Avilex Pharma ApS for the financial year 1 January - 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Independent auditor's report

- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 3 July 2023
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

Rasmus Bloch Jespersen
State Authorised Public Accountant
mne35503

Management's review

Company details

Name	Avilex Pharma ApS
Address, Postal code, City	Ole Maaløes Vej 3, 2200 København N
CVR no.	34 89 68 28
Established	27 December 2012
Registered office	København
Financial year	1 January - 31 December
Board of Directors	Raymond George Hill, Chairman Kristian Strømgaard Morten Døssing Jonathan Mark Treherne
Executive Board	Kristian Strømgaard
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

Management's review

Business review

The company's activities comprise to the development of novel drug candidates for the treatment of stroke and other neurodegenerative conditions, as well as any activity related thereto as determined by the Board of Directors.

Material misstatements

During the year, Management concluded the Company, in prior financial years, incorrectly omitted to identify and recognize at fair value the conversion rights embedded in the Company's convertible debt instruments separately from the liability element. Due to the significance of the matter the Company has treated the matter in accordance with the provisions in section 52(2) of the Danish Financial Statements Act regarding correction of material misstatements. Therefore, the error has been corrected as a material misstatement by restating comparatives and opening equity figures in the current-year financial statements.

In consequence of the restatement, loss for the year for 2021 have been adversely affected by - 705 thousand DKK, convertible debt instruments at 31 December 2021 have been adversely affected by -1,532 thousand DKK, derivative financial instruments at 31 December 2021 have been adversely affected by 5,110 thousand DKK, deferred tax at 31 December 2021 have been adversely affected by 787 thousand DKK. In total, the balance sheet total at 31 December 2021 has been adversely affected by 787 thousand DKK, and equity has been adversely affected by - 2,791 thousand DKK. The opening equity at 1 January 2021 has been adversely affected by -2,086 thousand DKK.

Financial review

The income statement for 2022 shows a profit of DKK 28,600 thousand against a loss of DKK 7,316 thousand last year, and the balance sheet at 31 December 2022 shows equity of DKK 4,917 thousand. Management considers the Company's financial performance in the year satisfactory.

In 2022, the company carried out a capital increase by conversion of convertible loans. Share capital has been increased by 61 thousand DKK and share-premium/retained earnings increased by 4,307 thousand DKK.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Financial statements 1 January - 31 December

Income statement

Note	DKK'000	2022	2021
	Revenue	45,479	0
	Gross profit	45,479	0
	Administrative expenses	-7,387	-3,200
	Operating profit/loss	38,092	-3,200
	Other operating income	0	1,987
	Research and development costs	-3,234	-7,472
	Profit/loss before net financials	34,858	-8,685
2	Financial income	3,979	77
3	Financial expenses	-2,176	-1,922
	Profit/loss before tax	36,661	-10,530
4	Tax for the year	-8,061	3,214
	Profit/loss for the year	28,600	-7,316
	Recommended appropriation of profit/loss	28,600	-7,316
	Retained earnings/accumulated loss	28,600	-7,316

Financial statements 1 January - 31 December

Balance sheet

Note	DKK'000	2022	2021
	ASSETS		
	Non-fixed assets		
	Receivables		
	Deferred tax assets	837	2,793
	Corporation tax receivable	109	1,644
	Joint taxation contribution receivable	461	0
	Other receivables	357	605
	Prepayments	0	64
		<u>1,764</u>	<u>5,106</u>
	Cash	29,827	598
	Total non-fixed assets	<u>31,591</u>	<u>5,704</u>
	TOTAL ASSETS	<u>31,591</u>	<u>5,704</u>
	EQUITY AND LIABILITIES		
	Equity		
	Share capital	470	409
	Share premium account	0	0
	Retained earnings	4,447	-28,460
	Total equity	<u>4,917</u>	<u>-28,051</u>
	Liabilities other than provisions		
5	Non-current liabilities other than provisions		
	Convertible debt instruments	19,963	25,867
	Derivative financial instruments	4,320	5,110
		<u>24,283</u>	<u>30,977</u>
	Current liabilities other than provisions		
	Bank debt	24	1
	Trade payables	2,122	2,567
	Other payables	245	210
		<u>2,391</u>	<u>2,778</u>
	Total liabilities other than provisions	<u>26,674</u>	<u>33,755</u>
	TOTAL EQUITY AND LIABILITIES	<u>31,591</u>	<u>5,704</u>

- 1 Accounting policies
- 6 Staff costs
- 7 Contractual obligations and contingencies, etc.
- 8 Collateral
- 9 Related parties

Financial statements 1 January - 31 December

Statement of changes in equity

DKK'000	Share capital	Share premium account	Retained earnings	Total
Equity at 1 January 2021	409	0	-19,058	-18,649
Adjustment of equity through corrections of errors	0	0	-2,086	-2,086
Adjusted equity at 1 January 2021	409	0	-21,144	-20,735
Transfer through appropriation of loss	0	0	-7,316	-7,316
Equity at 1 January 2022	409	0	-25,669	-25,260
Adjustment of equity through corrections of errors	0	0	-2,791	-2,791
Adjusted equity at 1 January 2022	409	0	-28,460	-28,051
Capital increase by conversion of convertible loans	61	4,307	0	4,368
Transfer through appropriation of profit	0	0	28,600	28,600
Transferred from share premium account	0	-4,307	4,307	0
Equity at 31 December 2022	470	0	4,447	4,917

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Avilex Pharma ApS for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Material misstatements

During the year, Management concluded the Company, in prior financial years, incorrectly omitted to identify and recognize at fair value the conversion rights embedded in the Company's convertible debt instruments separately from the liability element. Due to the significance of the matter the Company has treated the matter in accordance with the provisions in section 52(2) of the Danish Financial Statements Act regarding correction of material misstatements. Therefore, the error has been corrected as a material misstatement by restating comparatives and opening equity figures in the current-year financial statements.

In consequence of the restatement, loss for the year for 2021 have been adversely affected by - 705 thousand DKK, convertible debt instruments at 31 December 2021 have been adversely affected by -1,532 thousand DKK, derivative financial instruments at 31 December 2021 have been adversely affected by 5,110 thousand DKK, deferred tax at 31 December 2021 have been adversely affected by 787 thousand DKK. In total, the balance sheet total at 31 December 2021 has been adversely affected by 787 thousand DKK, and equity has been adversely affected by - 2,791 thousand DKK. The opening equity at 1 January 2021 has been adversely affected by -2,086 thousand DKK.

Reporting currency

The financial statements are presented in Danish kroner (DKK'000).

Income statement

Revenue

The Company has chosen IAS 18 as interpretation for revenue recognition.

Licence and royalty income is recognised over the term of the agreement in accordance with the contents of the agreement.

The company applies the milestone payment method to recognize revenue arising from the upfront and milestone payments from license and royalty agreements. The 'milestone payment method' (each milestone payment is recognized as revenue on successful completion of a milestone and payment is expected to be received) is a common application of the percentage of completion method in the life science industry. Accordingly, revenue from upfront and milestone payments is recognized when (i) it is probable that the economic benefits associated with the transaction will flow to the entity; (ii) the stage of completion of the transaction at the end of the reporting period can be measured reliably; and (iii) the costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

Administrative expenses

Administrative expenses include expenses incurred in the year for company management and administration, including expenses relating to administrative staff, Management, office premises and expenses as well as amortisation/depreciation of assets used for administrative purposes.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Research costs

The item includes research and development costs that do not qualify for capitalisation as well as amortisation of capitalised development costs.

Other operating income

Other operating income comprise items of a secondary nature relative to the Company's core activities, including gains on the sale of fixed assets.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts that relate to the financial reporting period. The items comprise interest income and expenses, e.g. from group entities and associates, declared dividends from other securities and investments, financial expenses relating to finance leases, realised and unrealised capital gains and losses relating to other securities and investments, exchange gains and losses and amortisation of financial assets and liabilities.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

Balance sheet

Intangible assets

Development costs and internally accumulated rights are recognised in the income statement as costs in the year of acquisition.

Leases

The Company has chosen IAS 17 as interpretation for classification and recognition of leases.

Payments relating to leases and any other rent agreements are recognised in the income statement over the term of the lease. The aggregate liabilities relating to leases and rent agreements are disclosed under "Contingent liabilities". Finance leases are not distinguish from operating leases.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Prepayments

Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.

Cash

Cash comprise deposits in bank accounts.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Liabilities

The Company has chosen IAS 39 as interpretation for liabilities.

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan.

Other liabilities are measured at net realisable value.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Convertible loans

Convertible debt instruments are initially broken down into a liability element and a conversion right. The conversion rights are recognized as derivative financial instruments, as the conversion rights as per the Company's convertible debt instruments are not convertible into a fixed number of shares for a fixed amount of cash (the 'fixed-for-fixed' criterion is not met). On initial recognition, the liability is recognised at the fair value of a similar liability without a conversion right. The remaining amount of the convertible debt is recognised as a derivative financial instrument. On subsequent recognition, the liability is measured at amortised cost until converted or repaid. The derivative financial instrument element is measured at fair value through profit or loss.

Fair value

The fair value measurement is based on the principal market. If no principal market exists, the measurement is based on the most advantageous market, i.e. the market that maximises the price of the asset or liability less transaction and/or transport costs.

All assets and liabilities which are measured at fair value, or whose fair value is disclosed, are classified based on the fair value hierarchy, see below:

Level 1: Value in an active market for similar assets/liabilities

Level 2: Value based on recognised valuation methods on the basis of observable market information

Level 3: Value based on recognised valuation methods and reasonable estimates (non-observable market information).

If a reliable fair value cannot be stated according to the above levels, the asset or liability is measured at cost.

DKK'000	2022	2021
2 Financial income		
Fair value adjustments of financial instruments	0	67
Other financial income	3,979	10
	<u>3,979</u>	<u>77</u>
3 Financial expenses		
Fair value adjustments of financial instruments	380	413
Other financial expenses	1,796	1,509
	<u>2,176</u>	<u>1,922</u>
4 Tax for the year		
Estimated tax charge for the year	6,566	-1,644
Deferred tax adjustments in the year	1,956	-1,570
Refund in joint taxation	-461	0
	<u>8,061</u>	<u>-3,214</u>

Financial statements 1 January - 31 December

Notes to the financial statements

5 Non-current liabilities other than provisions

Of the long-term liabilities, DKK 0 falls due for payment after more than 5 years after the balance sheet date.

The Company has issued multiple convertible debt instruments. The debt instruments were issued as part of the Company's financing. During the year, two of three convertible debt instruments have been converted and repaid, respectively. As of 31 December 2022, is one convertible debt instruments remaining, as further described below:

The Company entered a convertible loan in June 2015. The principal amount of the convertible loan is 2,410 thousand EUR, which is divided in five tranches. The first tranche of 650 thousand EUR was drawn in July 2015, the second tranche of 636 thousand EUR was drawn in December 2015, the third tranche of 600 thousand EUR was drawn in December 2017, the fourth tranche of 404 thousand EUR was drawn in May 2018, and the final tranche of 120 thousand EUR was drawn in October 2021.

The convertible loan, including accrued interest, has no fixed maturity date, and carries an interest rate of two percent above the three-month sterling LIBOR. The convertible loan includes several conversion and repayment features, which allows the lender to convert the loan into shares in the Company with a conversion discount of 0-20% to the share price of the Company or repayment of the loan, depending on which conversion or repayment feature is being utilized. The conversion and repayment features include: Conversion upon an 'exit event', repayment upon an 'exit event', conversion upon a qualified financing round, and conversion within a four week conversion period following the expiry of each calendar quarter, or repayment at any time after the third anniversary of the Effective Date upon written demand.

At initially recognition of each of the five tranches, the convertible loan has been separated into a liability component and a conversion/repayment option component (an embedded derivative), by allocating the difference between the fair value of the liability component and the proceeds to the conversion option. After initial recognition, the liability component is measured at amortized cost and the conversion option is measured at fair value through profit or loss.

The amortization of the liability component is calculated by use of an estimated market interest rate of 26 percent, 26 percent, 27 percent, 38 percent, and 72 percent for the first, second, third, fourth, and fifth tranches, respectively. The fair value of the conversion and repayment options has been calculated as the net present value by weighing in managements assumption about the weighted probabilities associated with timing and triggering event for conversion or repayment (level 3 of the fair value hierarchy). The following main assumptions on 31 December 2022 has been applied: conversion upon a qualified financing round or 'exit event' (85 percent), Event of default (15 percent), and repayment (0 percent).

Financial statements 1 January - 31 December

Notes to the financial statements

6 Staff costs

	2022	2021
Average number of full-time employees	<u>2</u>	<u>2</u>

7 Contractual obligations and contingencies, etc.

The Company is jointly taxed with Novo Holdings A/S which acts as management company, and has limited and alternative liability together with other jointly taxed group entities for payment of income taxes for income year 2022 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 23 September 2022.

8 Collateral

The Company has not provided any security or other collateral in assets at 31 December 2022.

9 Related parties

Avilex Pharma ApS' related parties comprise the following:

Parties exercising control

Related party	Domicile	Basis for control
Novo Holdings A/S	Tuborg Havnevej 19DK- 2900 Hellerup Municipality of Gentofte, Denmark	Participating interest

Information about consolidated financial statements

Parent	Domicile
Novo Nordisk Foundation	Tuborg Havnevej 19 DK-2900 Hellerup Municipality of Gentofte, Denmark

PENNEO

The signatures in this document are legally binding. The document is signed using Penneo™ secure digital signature. The identity of the signers has been recorded, and are listed below.

"By my signature I confirm all dates and content in this document."

Raymond Hill

Board of Directors

On behalf of: Avilex Pharma ApS

Serial number: raymond.hill@imperial.ac.uk

IP: 129.31.xxx.xxx

2023-07-03 09:13:43 UTC

Raymond Hill

Kristian Strømgaard

Executive Board

On behalf of: Avilex Pharma ApS

Serial number: 0d4ed4ee-e856-4bcc-9b48-834a2cd648a7

IP: 93.163.xxx.xxx

2023-07-03 11:32:20 UTC



Kristian Strømgaard

Chairman

On behalf of: Avilex Pharma ApS

Serial number: 0d4ed4ee-e856-4bcc-9b48-834a2cd648a7

IP: 93.163.xxx.xxx

2023-07-03 11:32:20 UTC



Kristian Strømgaard

Board of Directors

On behalf of: Avilex Pharma ApS

Serial number: 0d4ed4ee-e856-4bcc-9b48-834a2cd648a7

IP: 93.163.xxx.xxx

2023-07-03 11:32:20 UTC



Mark Treherne

Board of Directors

On behalf of: Avilex Pharma ApS

Serial number: treherne@ntlworld.com

IP: 82.4.xxx.xxx

2023-07-03 11:41:40 UTC

MTreherne

Morten Døssing

Board of Directors

On behalf of: Avilex Pharma ApS

Serial number: aed59909-9c7c-49c0-94f5-2077c0a7810e

IP: 152.73.xxx.xxx

2023-07-03 12:03:00 UTC



Penneo document key: 3F4QT-7GGMO-XQF2P-BE1GM-TH2KZ-65CG5

This document is digitally signed using Penneo.com. The digital signature data within the document is secured and validated by the computed hash value of the original document. The document is locked and timestamped with a certificate from a trusted third party. All cryptographic evidence is embedded within this PDF, for future validation if necessary.

How to verify the originality of this document

This document is protected by an Adobe CDS certificate. When you open the

document in Adobe Reader, you should see, that the document is certified by **Penneo e-signature service** <penneo@penneo.com>. This guarantees that the contents of the document have not been changed.

You can verify the cryptographic evidence within this document using the Penneo validator, which can be found at <https://penneo.com/validator>

PENNEO

The signatures in this document are legally binding. The document is signed using Penneo™ secure digital signature. The identity of the signers has been recorded, and are listed below.

"By my signature I confirm all dates and content in this document."

Rasmus Jespersen

State Authorised Public Accountant

On behalf of: EY Godkendt Revisionspartnerselskab

Serial number: CVR:30700228-RID:34311459

IP: 87.59.xxx.xxx

2023-07-04 18:57:26 UTC

NEM ID 

Penneo document key: 3F4QT-7GGMO-XQF2P-BE1GM-TH2KZ-65CG5

This document is digitally signed using Penneo.com. The digital signature data within the document is secured and validated by the computed hash value of the original document. The document is locked and timestamped with a certificate from a trusted third party. All cryptographic evidence is embedded within this PDF, for future validation if necessary.

How to verify the originality of this document

This document is protected by an Adobe CDS certificate. When you open the

document in Adobe Reader, you should see, that the document is certified by **Penneo e-signature service** <penneo@penneo.com>. This guarantees that the contents of the document have not been changed.

You can verify the cryptographic evidence within this document using the Penneo validator, which can be found at <https://penneo.com/validator>